OncoTartis
OncoTartis, Inc. is a private biotechnology company established in 2011. Company’s founding IP came from Prof. Andrei Gudkov’s laboratory at Roswell Park Cancer Institute (Buffalo, NY). OncoTartis develops a novel category of anti-cancer drugs directed against tissue-specific targets for a subset of cancers (breast, prostate, ovarian, melanoma and hematological malignancies). Its leading product OT-82 is a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor being developed to treat Acute Myeloid Leukemia (AML). Investigational New Drug application (IND) will be submitted to FDA in the forth quarter of 2017.
Tech Stack (13 technologies)
Frequently Asked Questions
What technologies does OncoTartis use?+
OncoTartis uses 13 technologies including Datadog, Google Analytics, Google Tag Manager.
What industry is OncoTartis in?+
OncoTartis operates in the Biometrics industry.
Where is OncoTartis based?+
OncoTartis is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026